Background: The aim of this study is to identify miRNAs able to predict the outcomes in breast cancer patients after neoadjuvant chemotherapy (NAC). Patients and methods: We retrospec-tively analyzed 24 patients receiving NAC and not reaching pathologic complete response (pCR). miRNAs were analyzed using an Illumina Next‐Generation‐Sequencing (NGS) system. Results: Event‐free survival (EFS) and overall survival (OS) were significantly higher in patients with up-regulation of let‐7a‐5p (EFS p = 0.006; OS p = 0.0001), mirR‐100‐5p (EFS s p = 0.01; OS p = 0.03), miR‐ 101‐3p (EFS p = 0.05; OS p = 0.01), and miR‐199a‐3p (EFS p = 0.02; OS p = 0.01) in post‐NAC samples, independently from breast cancer subtypes. At multivariate analysis, only let‐7a‐5p was significantly associated with EFS (p = 0.009) and OS (p = 0.0008). Conclusion: Up‐regulation of the above miRNAs could represent biomarkers in breast cancer.

Fuso, P., Di Salvatore, M., Santonocito, C., Guarino, D., Autilio, C., Mule, A., Arciuolo, D., Rinninella, A., Mignone, F., Ramundo, M., Di Stefano, B., Orlandi, A., Capoluongo, E. D., Nicolotti, N., Franceschini, G., Sanchez, A. M., Tortora, G., Scambia, G., Barone, C., Cassano, A., Let‐7a‐5p, mir‐100‐5p, mir‐101‐3p, and mir‐199a‐3p hyperexpression as potential predictive biomarkers in early breast cancer patients, <<JOURNAL OF PERSONALIZED MEDICINE>>, 2021; 11 (8): 1-17. [doi:10.3390/jpm11080816] [http://hdl.handle.net/10807/190389]

Let‐7a‐5p, mir‐100‐5p, mir‐101‐3p, and mir‐199a‐3p hyperexpression as potential predictive biomarkers in early breast cancer patients

Fuso, Paola;Di Salvatore, Mariantonietta;Santonocito, Concetta;Guarino, Donatella;Arciuolo, Damiano;Mignone, Flavio;Orlandi, Armando;Capoluongo, Ettore Domenico;Nicolotti, Nicola;Franceschini, Gianluca;Tortora, Giampaolo;Scambia, Giovanni;Cassano, Alessandra
2021

Abstract

Background: The aim of this study is to identify miRNAs able to predict the outcomes in breast cancer patients after neoadjuvant chemotherapy (NAC). Patients and methods: We retrospec-tively analyzed 24 patients receiving NAC and not reaching pathologic complete response (pCR). miRNAs were analyzed using an Illumina Next‐Generation‐Sequencing (NGS) system. Results: Event‐free survival (EFS) and overall survival (OS) were significantly higher in patients with up-regulation of let‐7a‐5p (EFS p = 0.006; OS p = 0.0001), mirR‐100‐5p (EFS s p = 0.01; OS p = 0.03), miR‐ 101‐3p (EFS p = 0.05; OS p = 0.01), and miR‐199a‐3p (EFS p = 0.02; OS p = 0.01) in post‐NAC samples, independently from breast cancer subtypes. At multivariate analysis, only let‐7a‐5p was significantly associated with EFS (p = 0.009) and OS (p = 0.0008). Conclusion: Up‐regulation of the above miRNAs could represent biomarkers in breast cancer.
2021
AREA06 - SCIENZE MEDICHE
Pubblicazione su rivista con Impact Factor
Inglese
Articolo in rivista
Inglese
Breast cancer treatment
Chemotherapy
Integrated ther-apies
MiRNAs
Next‐generation‐sequencing
Personalized medicine
Precision medicine
Subtypes breast cancer
Target therapy
Settore MED/06 - ONCOLOGIA MEDICA
MDPI
11
8
2021
1
17
17
816
info:eu-repo/semantics/article
Fuso, P., Di Salvatore, M., Santonocito, C., Guarino, D., Autilio, C., Mule, A., Arciuolo, D., Rinninella, A., Mignone, F., Ramundo, M., Di Stefano, B., Orlandi, A., Capoluongo, E. D., Nicolotti, N., Franceschini, G., Sanchez, A. M., Tortora, G., Scambia, G., Barone, C., Cassano, A., Let‐7a‐5p, mir‐100‐5p, mir‐101‐3p, and mir‐199a‐3p hyperexpression as potential predictive biomarkers in early breast cancer patients, <<JOURNAL OF PERSONALIZED MEDICINE>>, 2021; 11 (8): 1-17. [doi:10.3390/jpm11080816] [http://hdl.handle.net/10807/190389]
open
262
Fuso, Paola; Di Salvatore, Mariantonietta; Santonocito, Concetta; Guarino, Donatella; Autilio, C.; Mule, A.; Arciuolo, Damiano; Rinninella, A.; Mignon...espandi
20
art_per_29
03. Contributo in rivista::Articolo in rivista, Nota a sentenza
File in questo prodotto:
File Dimensione Formato  
Let-7a-5p, miR-100-5p, miR-101-3p, and miR-199a-3p Hyperexpression as Potential Predictive Biomarkers in Early Breast Cancer Patients.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 2.41 MB
Formato Adobe PDF
2.41 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/190389
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 23
social impact